







Weight Regain in Formerly Obese Mice Hastens Development of Hepatic Steatosis Due to Impaired Adipose Tissue Function

Brian F. Zamarron ¹, Cara E. Porsche ¹, Danny Luan², Hannah R. Lucas², Taleen A. Mergian², Gabriel Martinez-Santibanez ³, Kae Won Cho⁴, Jennifer L. DelProposto⁵, Lynn M. Geletka⁵, Lindsey A. Muir ⁵, Kanakadurga Singer ^{1,5}, and Carey N. Lumeng ^{1,3,5}

Objective: Weight regain after weight loss is common, and there is evidence to suggest negative effects on health because of weight cycling. This study sought to investigate the impact of weight regain in formerly obese mice on adipose tissue architecture and stromal cell function.

Methods: A diet-switch model was employed for obesity induction, weight loss, and weight regain in mice. Flow cytometry quantified adipose tissue leukocytes in adipose tissue. Liver and adipose tissue depots were compared to determine tissue-specific effects of weight cycling.

Results: Epididymal white adipose tissue of formerly obese mice failed to expand in response to repeat exposure to high-fat diet and retained elevated numbers of macrophages and T cells. Weight regain was associated with disproportionately elevated liver mass, hepatic triglyceride content, serum insulin concentration, and serum transaminase concentration. These effects occurred despite an extended 6-month weight loss cycle and they demonstrate that formerly obese mice maintain durable alterations in their physiological response to weight regain. Conditioned media from epididymal adipose tissue of formerly obese mice inhibited adipogenesis of 3T3-L1 preadipocytes, suggesting a potential mechanism to explain failed epididymal adipose tissue expansion during weight regain.

Conclusions: Metabolic abnormalities related to defects in adipose tissue expansion and ongoing dysfunction manifest in formerly obese mice during weight regain.

Obesity (2020) **28**, 1086–1097.

Introduction

Obesity is associated with increased risk for several comorbidities, including metabolic syndrome, type 2 diabetes, and cardiovascular disease. Weight loss, through caloric restriction or bariatric surgery, improves metabolic dysfunction and can reduce measures of inflammation both systemically and within adipose tissue (1–3). Unfortunately, long-term maintenance of even 10% weight loss is difficult, and only ~20% of people maintain this reduction beyond 1 year (4), regardless of dietary or surgical weight loss (5,6).

Study Importance

What is already known?

- ▶ Weight cycling may have adverse metabolic consequences.
- ▶ Obesity alters the architecture of adipose tissue.
- ▶ Mechanisms of adverse long-term consequences of obesity are not well understood.

What does this study add?

- ▶ Formerly obese mice demonstrate durable changes in epididymal adipose tissue architecture that limit proper depot expansion after rechallenge with high-fat diet.
- ▶ The failure of adipose tissue to remodel and permit healthy expansion continues up to 6 months after weight loss in mice and exacerbates hepatic steatosis and liver dysfunction.
- ▶ Weight cycling sustains CD11c⁺ adipose tissue macrophages, CD8⁺ adipose tissue T cells, and Col1⁺ preadipocytes.

How might these results change the focus of clinical practice?

- ▶ The results emphasize the importance of early obesity treatment and prevention.
- ▶ Long-term consequences of obesity even after weight loss can impact metabolic flexibility.

¹ Graduate Program in Immunology, University of Michigan Medical School, Ann Arbor, Michigan, USA. Correspondence: Carey N. Lumeng (clumeng@umich.edu)

² College of Literature Sciences and Arts, University of Michigan, Ann Arbor, Michigan, USA ³ Graduate Program in Cellular and Molecular Biology, University of Michigan Medical School, Ann Arbor, Michigan, USA ⁴ Soonchunhyang Institute of Medi-Bio Science, Soonchunhyang University, Cheonan-si, Chungcheongnam-do, Korea ⁵ Department of Pediatrics, University of Michigan Medical School, Ann Arbor, Michigan, USA.

An open question in the field is whether weight regain and/or weight cycling adversely alters metabolic health. Clinical studies have suggested that weight cycling is not associated with increased risk of metabolic disease when compared with those with sustained overweight or obesity (7-9). However, there are studies showing that weight cycling carries a higher risk for diabetes and adverse cardiovascular events than non-weight-cycling individuals (10-12). Few studies have evaluated physiological responses or alterations in tissue-specific metabolic parameters during the weight regain cycle. Rodent studies have found altered fatty acid metabolism with increased lipoprotein lipase, serum triglycerides, and serum cholesterol during high-fat diet (HFD) refeeding beyond what is observed in rodents maintained on HFD ad libitum (13-15). Weight cycling was also observed to increase visceral fat mass and inflammatory markers within adipose tissue in association with insulin resistance (16-18).

These observations suggest that weight regain in lean individuals who used to have obesity may result in unique patterns of dysfunction in metabolic tissues, leading to metabolic disease risk. Consistent with this, lean adults who used to be children with obesity were shown to retain a fivefold higher risk for elevated hemoglobin A1c (19). Inflammatory gene expression in adipose tissue of humans who used to have obesity remains high compared with lean individuals (20-22). Our group and others have demonstrated that weight loss does not resolve adipose tissue inflammation and insulin sensitivity in mice (23-26). Inflammatory CD11c⁺ macrophages and crown-like structures (CLS) are maintained within adipose tissue despite extended weight loss associated with persistent impairment in insulin tolerance (23).

We sought to understand the metabolic and inflammatory implications of weight cycling using a mouse model of weight gain in formerly obese mice. We found that the epididymal white adipose tissue (eWAT) of formerly obese mice had impaired expansion and reduced lipid storage capacity with HFD refeeding. Weight regain was also associated with increased hepatic triglyceride storage and markers of hepatocyte dysfunction. This failure of eWAT expansion occurred despite the presence of an expanded preadipocyte pool. Furthermore, eWAT from formerly obese mice secreted factors that inhibited adipogenesis *in vitro*, which suggests a mechanism for impaired adipose expansion and persistent adipose tissue dysfunction.

Methods

Animals and animal care

At 6 weeks of age, male C57BL/6J mice (Jackson, Bar Harbor, Maine) were fed a control normal diet (ND; LabDiet, St. Louis, Missouri; PicoLab 5L0D, 4.09 kcal/g, 28.7% calories from protein, 13.4% calories from fat, 57.9% calories from carbohydrate) or HFD (Research Diets, New Brunswick, New Jersey; D12492, 5.21 kcal/g, 20% calories from protein, 60% calories from fat, 20% calories from carbohydrate).

Glucose tolerance tests (GTT) and insulin tolerance tests (ITT) were performed after 6 hours of fasting. Mice were injected intraperitoneally with D-glucose (0.7 g/kg) for GTT and human recombinant insulin (1 U/kg) for ITT. Glucose was measured using FreeStyle Lite blood glucose monitors (Abbott, Abbott Park, Illinois). Insulin was measured by enzyme-linked immunosorbent assay (ELISA; Crystal Chem, Elk Grove Village, Illinois). Energy metabolism was measured using Comprehensive Lab Animal Monitoring System analysis (CLAMS; Columbus Instruments,

Columbus, Ohio). All mouse procedures were approved by the University of Michigan Committee on Use and Care of Animals and were conducted in compliance with the Institute for Laboratory Animal Research Guide for the Care and Use of Laboratory Animals.

Gene expression analysis

RNA was extracted from tissues using Trizol LS (Life Technologies, Carlsbad, California) and complementary DNA (cDNA) generated using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Waltham, Massachusetts). SYBR Green PCR Master Mix and the StepOnePlus Real-Time PCR System (Applied Biosystems) were used for real-time quantitative polymerase chain reaction (PCR) using *Gapdh* expression as an internal control for data normalization. Samples were assayed in duplicate, and relative expression was determined using $2^{-\Delta\Delta CT}$ method (primers in Supporting Information Table S1).

Immunoblotting and immunofluorescence

Adipose tissue was homogenized in radioimmunoprecipitation assay lysis buffer with phosphatase inhibitors. Protein concentration was determined using Bio-Rad Protein Assay Dye Reagent (Hercules, California). Antibodies used for immunoblotting were as follows: PPAR γ (81B8), IRS-1, phospho-Akt (Ser473), AKT, adiponectin (C45B10) (Cell Signaling Technology, Danvers, Massachusetts), and β -actin (AC-40) (Sigma-Aldrich, St. Louis, Missouri). Proteins were imaged using Odyssey infrared imaging system (Li-Cor Bioscience, Lincoln, Nebraska). Immunofluorescence was performed as previously described in adipose tissue explants and fixed overnight in a 2% paraformaldehyde solution (27). Antibodies used for immunofluorescence were caveolin (BD Pharmingen, San Diego, California) and Mac2 (galectin-3) (eBioM3/38) (eBioscience, San Diego, California).

Isolation of adipose tissue stromal vascular fraction and flow cytometry

Adipose tissue was digested in Roswell Park Memorial Institute-1640 medium (Invitrogen, Carlsbad, California) with 0.5% bovine serum albumin (BSA) and 1 mg/mL of type II collagenase on a rocking platform for 25 minutes at 37°C. The stromal vascular fraction (SVF) was separated from adipocytes by centrifugation. The following antibodies were used for flow cytometry following Fc block: CD45 (30-F11), CD3e (145-2C11), CD4 (GK1.5), CD8a (53-6.7), CD11c (N418), Sca-1 (Ly-6A/E) (D7), CD31 (390) (eBioscience), PDGFR α (RM0004-3G28) (Abcam, Cambridge, UK), and CD64 (X54-5/7.1) (BD Pharmingen). For intracellular collagen staining, cells were incubated in Fc block and then stained with surface antibodies for 45 minutes at 4°C. Intracellular stains were performed using Forkhead Box P3 Fix/Perm Buffer (BioLegend, San Diego, California) followed by a 15-minute block with 0.5% goat serum, a 1-hour incubation with 0.5 μ g of rabbit collagen type I antibody (Rockland, Limerick, Pennsylvania), three washes, and 30-minute incubation with 0.2 μ g of goat anti-rabbit Alexa Fluor 647 antibody (Thermo Fisher Scientific, Carlsbad, California). Analysis was performed using a BD FACSCanto II (BD Biosciences, San Jose, California) and FlowJo v.10 (Treestar, Ashland, Oregon).

Explant conditioned media

Two hundred milligrams of epididymal adipose tissue explants were cultured in serum-free AIM V Medium with AlbuMAX and BSA (Life Technologies) to create conditioned media (CM). Confluent 3T3-L1 cells were treated with a 1:1 mixture of CM and methylisobutylxanthine,

dexamethasone, insulin differentiation media (0.5mM methylisobutylxanthine, 1μM dexamethasone, and 10-μg/mL human recombinant insulin in DMEM); after 3 days, media was replaced with another 1:1 mixture of CM and insulin medium (10 μg of insulin in DMEM). For tumor necrosis factor alpha (TNFα) neutralizing experiments, CM was treated for 1 hour with 100 ng/mL of blocking antibody before using the CM in 3T3-L1 cultures at a final concentration of 50 ng/mL

(D2H4 mAb; Cell Signaling Technology). For cytokine and chemokine treatments (10 ng/mL; PeproTech, Rocky Hill, New Jersey), 3T3-L1 cells were treated during both phases of differentiation. Mouse Cytokine Antibody Array (R&D Systems, Minneapolis, Minnesota) was used to evaluate adipose tissue explant CM (48 hours, pooled from three mice). Quantitation was performed by ImageJ (NIH, Bethesda, Maryland) after background subtraction and normalization.




Figure 1 Weight loss and HFD rechallenge model. (A) Diagram of experimental paradigm of obesity induction, weight loss, and HFD rechallenge model and longitudinal weight. Body weight after (B) weight loss and (C) HFD rechallenge. (D) Energy expenditure after weight loss and (E) food intake 1 week after starting HFD rechallenge phase. (F,G) Glucose tolerance testing (GTT) at 2 and 4 weeks of HFD rechallenge. (H) Insulin tolerance testing (ITT) after 6 weeks of HFD rechallenge. (I) Fasted blood glucose. (J) Fasted serum insulin. For panels A-J, n=4. *P<0.05, **P<0.01, ****P<0.0001; significance was compared only for ST-HFD versus RC-HFD, LT-HFD versus RC-HFD, ND versus WL, or WL versus HFD (20 weeks).

Liver triglyceride quantification

Approximately 100 mg of frozen liver samples was homogenized in 300 μ L of lysis buffer (10% NP-40, 50mM Tris-HCl pH 7.5, and 100mM NaCl), and 200 μ L of chloroform was added before drying in a vacuum concentrator. Lipids were extracted using 400 μ L of chloroform and transferred to new tubes for drying. Lipids were reconstituted with 1 mL per 100 mg of tissue of a butanol mixture (6% butanol, 3.33% Triton-X100, and 0.66%

methanol) and quantified using the Infinity Triglyceride Quantification Kit (Thermo Fisher Scientific, Waltham, Massachusetts).

Statistical analyses

All values are reported as mean (SEM). Statistical significance was determined using unpaired two-tailed Student *t* test or one-way ANOVA for multiple groups using Fisher least significant difference test. All




Figure 2 HFD rechallenge increases epididymal adipose tissue CLS and reduces expression of proteins essential for mature adipocyte development and function. (A) Total epididymal WAT (eWAT) weight and as a percent of total body weight ($n=4$). (B) eWAT adipocyte size distribution ($n=3$ for RC-HFD and $n=4$ for other diet conditions). (C) Immunofluorescence and hematoxylin and eosin (H&E) stained eWAT slides representative for each diet condition showing CLS development and maintenance. (D) Representative immunoblots from eWAT showing select adipocyte maturation and insulin signaling proteins. (E) Quantification of densitometry measurements from immunoblots of whole eWAT ($n=3$). (F) Expression of adipocyte maturation genes from eWAT ($n=4$). (G) Inguinal WAT (iWAT) total weight and as percent of total body weight ($n=4$). (H) Ratio of iWAT to eWAT after HFD rechallenge ($n=4$). (I) H&E stained iWAT slides representative for each diet condition. Two-way ANOVA with Dunnett multiple comparisons for F. * $P<0.05$, ** $P<0.01$, **** $P<0.0001$; significance was compared only for ST-HFD versus RC-HFD, LT-HFD versus RC-HFD, or ND versus WL. [Color figure can be viewed at wileyonlinelibrary.com]

gene expression data were compared using two-way ANOVA with Dunnett multiple comparisons correction. All statistical analysis was performed using GraphPad Prism V6.05 (San Diego, California).

Results

HFD rechallenged mice have reduced eWAT mass and hyperinsulinemia compared with mice without prior HFD exposure

We used a dietary model of weight loss and regain in mice to assess the differences in metabolic and inflammatory measures between mice fed similar durations of HFD with and without preconditioning with weight loss (23). Male C57BL/6J mice were fed HFD or ND for 12 weeks. Obese mice were then maintained on HFD or switched to ND for 8 weeks to induce weight loss. Mice were then rechallenged with HFD for 6 weeks (RC-HFD). Age-matched control groups were mice fed ND for 20 weeks prior to the same 6-week short-term HFD challenge (ST-HFD) or mice continuously fed HFD long term for all 26 weeks (LT-HFD) (Figure 1A).

After weight loss, body weight in the RC-HFD group was the same as age-matched mice fed ND (RC-HFD: 32.1 [1.5] g; ST-HFD: 30.4 [1.1] g) (Figure 1B). After HFD rechallenge, RC-HFD mice weight was significantly higher (52.7 [1.5] g) than ST-HFD mice (43.9 [5.2] g) fed for the same duration but was not significantly different from LT-HFD mice (52.0 [4.0] g) (Figure 1C). Compared with the ST-HFD group, total body energy expenditure was reduced in the RC-HFD mice and further reduced in the LT-HFD group (Figure 1D). One week after initiating HFD rechallenge, RC-HFD mice had higher food intake than ST-HFD and LT-HFD mice (Figure 1E). The reduced energy expenditure and increased HFD intake likely explain the significantly elevated body weight of RC-HFD mice compared with ST-HFD mice.

GTT results were similar between RC-HFD and ST-HFD mice after 2 and 4 weeks of HFD (Figure 1F-1G). ITT revealed comparable insulin sensitivity between ST-HFD and RC-HFD mice and impaired insulin tolerance in LT-HFD mice (Figure 1H). After 6 weeks of HFD feeding, fasting glucose was elevated in all three HFD groups compared with lean controls but did not differ between the HFD groups (Figure 1I). Serum insulin levels were significantly increased in RC-HFD mice compared with ST-HFD mice (Figure 1J). Overall, these results suggest that formerly obese mice required elevated insulin levels to maintain similar glycemic control as mice that had not been previously exposed to HFD.

Markers of dysfunction in eWAT but not inguinal WAT of formerly obese mice after HFD rechallenge

Despite increased total body weight, eWAT in RC-HFD mice was significantly smaller than ST-HFD mice (Figure 2A). eWAT

adipocyte size in ST-HFD, RC-HFD, and LT-HFD was not significantly different (Figure 2B), suggesting impairments in adipocyte hyperplasia/adipogenesis in RC-HFD and LT-HFD groups. Histology demonstrated that ST-HFD mice had minimal CLS while RC-HFD and LT-HFD eWAT had high CLS content (Figure 2C). Immunoblots revealed reductions in proteins associated with mature differentiated adipocytes, including PPAR γ , IRS-1, and AKT, in RC-HFD and LT-HFD eWAT compared with ST-HFD eWAT (Figure 2D-2E). Gene expression showed reduced *Insrl*, *Irs1*, *Cebpa*, *Pref1*, and *Glut4* expression in ST-HFD, LT-HFD, and RC-HFD eWAT compared with ND. Compared with ST-HFD mice, expression of these same genes as well as *Cebpa*, *Pref1*, and *Glut4* was further reduced in RC-HFD and LT-HFD mice (Figure 2F).

To identify depot-specific effects, we evaluated inguinal subcutaneous WAT (iWAT). In contrast to eWAT, iWAT weight was increased in RC-HFD mice, compared with ST-HFD, and was similar to LT-HFD (Figure 2G). ST-HFD had similar ratios of iWAT to eWAT as ND and weight loss (WL) mice. In contrast, RC-HFD and LT-HFD had significantly greater iWAT to eWAT ratios (Figure 2H), suggesting restricted lipid storage in eWAT with prior HFD exposure. No substantial differences in iWAT CLS development were seen between diet groups (Figure 2I). Gene expression from iWAT revealed HFD-induced reductions in most mature adipocyte genes compared with ND, but no significant differences between ST-HFD, RC-HFD, and LT-HFD groups were observed except for *Lpl*, which was increased in ST-HFD iWAT (Supporting Information Figure S1A). Inflammatory cytokine gene expression was also evaluated in iWAT, revealing no significant differences between groups (Supporting Information Figure S1B). Overall, in contrast to eWAT, iWAT expansion in RC-HFD mice was not impaired compared with ST-HFD mice but was associated with a lack of CLS development.

HFD rechallenge increases hepatic steatosis and markers of liver dysfunction

Liver weights were significantly elevated in RC-HFD mice compared with ST-HFD mice (Figure 3A-3B). Liver histology from ND and WL mice was similar, showing resolution of hepatic steatosis after 8 weeks off the HFD (Figure 3C). By histology, RC-HFD mice had significantly elevated hepatic steatosis compared with ST-HFD and similar to LT-HFD mice (Figure 3C-3D). Total hepatic triglyceride content was more than twofold higher in RC-HFD and LT-HFD mice when compared with ST-HFD (Figure 3E-3F). Serum triglyceride concentrations were similar between groups (Figure 3G). Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were quantified as markers of hepatocyte stress and damage. RC-HFD mice had significantly elevated AST and ALT compared with ST-HFD mice that were similar to the LT-HFD group (Figure 3H). Overall, this demonstrates




Figure 3 Increased liver steatosis and signs of liver damage with HFD rechallenge. (A) Representative H&E stained slides from livers showing steatosis development and (B) percent of surface area with lipid involvement from H&E images ($n \geq 4$). (C) Liver weight and (D) liver as a percent of total body weight ($n = 4$). (E) Liver triglyceride concentration and (F) total liver triglyceride content ($n = 4$). Serum concentrations for (G) triglycerides ($n \geq 4$), (H) aspartate aminotransferase (AST, left; $n = 4$), and alanine aminotransferase (ALT, right; $n = 4$). * $P < 0.05$, ** $P < 0.01$, **** $P < 0.0001$; significance was only compared for ST-HFD versus RC-HFD, LT-HFD versus RC-HFD, or ND versus WL. [Color figure can be viewed at wileyonlinelibrary.com]

that prior HFD exposure potentiates hepatocellular dysfunction and steatosis upon repeat challenge to HFD.

To determine whether the increased hepatic triglyceride content was due to increased hepatic lipogenesis, we evaluated several hepatic lipid

and glucose metabolism genes. Compared with ST-HFD and RC-HFD mice, LT-HFD induced *Lpl* and *Pparg* expression but showed no significant differences in expression of *Scd1*, *Srebp1*, *Fasn*, *Me1*, *Acaca*, *Fabp1*, *G6pc*, *Pck1*, or *Gck*. No differences in expression of genes involved in lipid metabolism were seen between RC-HFD and ST-HFD




Figure 4 HFD rechallenge after 24 weeks of weight loss reveals prolonged defects in epididymal WAT (eWAT) expansion capacity. (A) Cartoon showing extended ND-switch period of 24 weeks followed by 6 weeks of HFD rechallenge. (B) Body weight of mice after 24 weeks of ND-switch and then rechallenging with HFD. (C) eWAT weight and (D) inguinal WAT (iWAT) weight after HFD rechallenge. (E) Representative immunofluorescence images showing CLS retention. (F) Fasting blood glucose after HFD challenge. (G) Representative liver hematoxylin and eosin (H&E) slides showing steatosis development. (H) Liver weight and (I) total liver triglyceride content after HFD rechallenge. For panels B-D, F, H, and I, $n=4$. * $P<0.05$, ** $P<0.01$, *** $P<0.001$; significance was compared only for Ex-ST-HFD versus Ex-RC-HFD or Ex-LT-HFD versus Ex-RC-HFD. [Color figure can be viewed at wileyonlinelibrary.com]

livers (Supporting Information Figure S2A-S2B). These results suggest that the increased hepatic triglyceride storage was not the result of increased de novo lipogenesis in liver. Liver inflammatory gene expression revealed significantly increased expression of *Tnfa* in RC-HFD and LT-HFD mice compared with ST-HFD but no differences in *Il1b* and *Il6* expression (Supporting Information Figure S2C). Leukocyte gene expression for *F480* and *Cd3* was elevated in LT-HFD mice but was not significantly different between ST-HFD and RC-HFD mice (Supporting Information Figure S2D).

HFD rechallenge effects are retained despite extended weight loss

To evaluate the durability of the effects of prior obesity, we extended the duration of weight loss to 24 weeks and then rechallenged mice with HFD for 6 weeks (Ex-RC-HFD) (Figure 4A). Age-matched control mice were maintained on extended ND (Ex-ST-HFD) and extended HFD (Ex-LT-HFD). The Ex-RC-HFD group weighed significantly more than age-matched Ex-ST-HFD mice and significantly less than Ex-LT-HFD mice (Figure 4B). eWAT was reduced in Ex-RC-HFD and Ex-LT-HFD mice compared with Ex-ST-HFD mice in both total mass and as a

percent of body weight (Figure 4C). iWAT weight was not significantly different between Ex-RC-HFD and Ex-ST-HFD mice, but both were less than Ex-LT-HFD (Figure 4D). Immunofluorescence of eWAT revealed increased CLS in Ex-RC-HFD and Ex-LT-HFD mice compared with Ex-ST-HFD mice (Figure 4E). Gene expression for adipocyte maturation in eWAT revealed no significant differences between diet conditions (Supporting Information Figure S3A). Fasting blood glucose of Ex-RC-HFD mice was significantly elevated compared with Ex-LT-HFD mice but not when compared with Ex-ST-HFD mice (Figure 4F).

Liver histology revealed substantial steatosis in all three diet conditions (Figure 4G). Total and percent liver weight was significantly elevated in Ex-RC-HFD and Ex-LT-HFD mice compared with Ex-ST-HFD (Figure 4H). Liver triglycerides were increased in the Ex-RC-HFD and Ex-LT-HFD mice compared with Ex-ST-HFD mice (Figure 4I). Liver gene expression revealed no significant differences between groups for lipid and glucose metabolism genes assessed (Supporting Information Figure S3B-S3C). Overall, the results show that increasing the recovery time off HFD from 8 to 24 weeks did not improve eWAT expansion or diminish the development of hepatic steatosis with HFD rechallenge.




Figure 5 Increased CD11c⁺ adipose tissue macrophage (ATM) accumulation and inflammation with HFD rechallenge. (A) Frequency of CD45⁺ leukocytes of all epididymal WAT (eWAT) SVF. (B) Total ATM content per eWAT pad and (C) frequency of all CD45⁺CD64⁺ ATMs that express CD11c. (D) Total T-cell content per eWAT pad. Frequency of (E) CD4⁺ and (F) CD8⁺ cells of all adipose tissue T cells. (G) Expression of select inflammatory cytokine genes from whole eWAT. For panels A-F, n=4; for panel G, n=3 for ND and WL diet conditions and n=4 for ST-HFD, RC-HFD, and LT-HFD conditions. *P<0.05, **P<0.01, ***P<0.001; significance was compared only for ST-HFD versus RC-HFD, LT-HFD versus RC-HFD, or ND versus WL.

eWAT leukocyte content is increased after HFD rechallenge

Adipose tissue leukocyte composition was analyzed to determine the impact of HFD rechallenge on eWAT stromal content. Flow cytometry revealed increased total leukocyte accumulation in the eWAT SVF of RC-HFD compared with ST-HFD but less than what was observed in LT-HFD mice (Figure 5A). The total number of eWAT adipose tissue macrophages (ATM) was also significantly increased in RC-HFD mice as well as the frequency of CD11c⁺ ATMs (Figure 5B-5C). Analysis of adipose tissue T-cell populations showed a trend toward an increase in total T-cell content in RC-HFD mice. However, there was a significantly higher frequency of CD8⁺ T cells in RC-HFD mice compared with ST-HFD mice (Figure 5D-5F). eWAT inflammatory cytokine expression showed *Tnfa* was increased in RC-HFD and LT-HFD mice compared with ST-HFD, but *Il1β* and *Il6* expression did not differ between groups (Figure 5G). Overall, HFD rechallenge promoted increased inflammation and accelerated accumulation of leukocytes within eWAT.

Obesity imposes durable increase in eWAT preadipocytes despite weight loss

Our observations of decreased eWAT expansion and similar adipocyte size in RC-HFD compared with ST-HFD mice suggest that adipogenesis may be impaired in formerly obese mice. We quantified adipose tissue preadipocytes in the flow cytometry defined as CD45⁺CD31⁻Sca-1⁺PDGFRα⁺ cells (28,29). After weight loss, eWAT had an increase in preadipocytes compared with lean mice that was comparable to HFD mice (Figure 6A). This increase in preadipocytes was not observed in iWAT (Figure 6B). Because the increase in preadipocytes correlated

with adipose tissue fibrosis during weight loss (23), we used intracellular flow cytometry to quantify collagen I+ (Col1⁺) preadipocytes in lean, obese, and WL groups (Figure 6C-6D). This demonstrated an increase in Col1⁺ preadipocytes in WL and HFD-fed mice in eWAT. Col1⁺ preadipocytes were induced by obesity in iWAT but were reduced after weight loss. This suggests that eWAT of formerly obese mice contained an expanded preadipocyte pool that expressed profibrotic markers and correlated with an inability to properly expand during HFD rechallenge.

eWAT of formerly obese mice secretes factors that inhibit adipogenesis

To examine the mechanism of this failure of adipose tissue to expand after HFD rechallenge, we utilized an *in vitro* model. CM was collected from eWAT explant cultures from ND and WL mice in serum-free media for 24 hours and added to 3T3-L1 during induction of adipogenesis. CM from WL mice significantly increased genes normally associated with preadipocyte cells, rather than mature adipocytes, including *Pref1*, *Colla1*, *Col3a1*, *Acta2*, and *Fnl* expression compared with ND CM treatment (Figure 7A-7B). Oil Red O staining showed that both WL and HFD CM treatment significantly reduced lipid storage compared with ND CM treatment (Figure 7C-7D).

To determine what factors might be responsible for inhibiting adipogenesis, cytokine arrays evaluated eWAT explant CM from ND, WL, and HFD mice after 48 hours in culture. We observed that IL1ra and chemokines CCL4, CXCL9, CCL5, and CCL12 were elevated in WL CM compared with ND CM (Figure 7E). Treatment of 3T3-L1 cells during differentiation with these chemokines revealed a small, but significant, reduction in differentiation assessed by Oil Red O (Figure 7F). While




Figure 6 Epididymal WAT (eWAT) of formerly obese mice maintains elevated numbers of preadipocytes. CD45⁺CD31⁻Sca-1⁺PDGFRα⁺ preadipocytes in ND, WL, and HFD mice were quantified by flow cytometry in (A) eWAT ($n=4$ for all conditions) and (B) inguinal WAT (iWAT) ($n=4$ for ND and $n=3$ for WL and HFD). Quantity of collagen I (Col1⁺) preadipocytes was determined by intracellular flow cytometry in (C) eWAT ($n=4$ for all conditions) and (D) iWAT ($n=4$ for ND and $n=3$ for WL and HFD). * $P<0.05$, *** $P<0.001$; significance was compared only for ND versus WL or WL versus HFD (20 weeks).




Figure 7 CM from epididymal WAT (eWAT) explants of formerly obese mice inhibits adipocyte differentiation and reduces lipogenesis. Gene expression for (A) adipocyte maturation genes and (B) collagen genes after differentiation induction in the presence of eWAT explant CM from the respective diet conditions ($n=4$). Oil Red O staining of lipid droplets within differentiated adipocytes shown as (C) representative micrographs and (D) relative total extracted Oil Red O content from wells ($n=3$). (E) eWAT explant multiplex cytokine array ($n=1$ for ND and $n=2$ for WL and HFD). (F) Extracted relative Oil Red O content from differentiated 3T3-L1 cells after treatment with (left) 10 ng/mL of individual chemokines identified from multiplex cytokine array or (right) simultaneous treatment with all identified chemokines at 10 ng/mL each ($n\geq 3$). (G) Extracted relative Oil Red O absorbance after treatment with CM from ST-HFD, RC-HFD, or LT-HFD with or without the addition of 50 ng/mL of neutralizing anti-TNF α antibody (α TNF) during differentiation ($n\geq 4$). * $P<0.05$, ** $P<0.01$, *** $P<0.001$, **** $P<0.0001$; significance was compared only for ST-HFD versus RC-HFD, LT-HFD versus RC-HFD, or ND versus WL unless otherwise noted. Undiff., undifferentiated control; Diff., differentiated control; All Chemok., all identified chemokines. [Color figure can be viewed at wileyonlinelibrary.com]

treatment with single chemokines only minimally inhibited differentiation, treatment with all four simultaneously abolished inhibition.

TNF α is a known potent inhibitor of adipogenesis (30). Because gene expression for *Tnfa* was elevated in WL, RC-HFD, and

LT-HFD eWAT (Figure 5G), we sought to determine if TNF α might play a role in inhibiting adipogenesis in our culture model. TNF α -neutralizing antibody was added to CM from eWAT explants before treating 3T3-L1 cells. Treatment of differentiating 3T3-L1 cells with ST-HFD, RC-HFD, or LT-HFD CM resulted in equivalent inhibition

of differentiation and was similar to what was observed after WL CM or HFD CM treatment (Figure 7G). Exposure to TNF α -neutralizing antibody caused small but significant improvement when added to ST-HFD eWAT CM, but no differences were seen in the RC and LT-HFD CM. Overall, the results show that eWAT of obese and formerly obese mice secrete multiple factors that may contribute to impaired adipogenesis and the failure to induce new adipocyte formation upon HFD rechallenge.

Discussion

We have previously demonstrated that eWAT of formerly obese mice maintains activated leukocytes' abnormal eWAT structure (23). In this study, we assess the metabolic and inflammatory consequences of re-challenging formerly obese mice with HFD. Our major finding was that basic functions of adipose tissue to respond to HFD were permanently impaired in formerly obese mice. eWAT of formerly obese mice was unable to efficiently store excessive nutrients and led to increased ectopic lipid storage in the liver and iWAT upon HFD rechallenge. This derangement persists despite extended time off HFD and suggests a permanent impact of obesity on eWAT function and architecture. Compared with weight-matched mice not previously exposed to HFD, RC-HFD mice had exaggerated induction of ATMs, increased CD8⁺ tissue T cells, and increased inflammatory cytokine expression. HFD challenge of formerly obese mice led to reduced eWAT mass with identical adipocyte size compared with ST-HFD mice, suggesting impaired adipocyte hyperplasia. The mechanism behind these findings relates to an increased number of Col1⁺ preadipocytes as well as eWAT secreted chemokines that can inhibit *in vitro* adipogenesis.

Our observations are similar to other weight-cycling models in rodents that suggest deleterious effects of repeat exposure to HFD (16-18). Our longer initial HFD exposure (12 weeks) is designed to examine the impact of a prolonged obese state. We note that the RC-HFD group is exposed to HFD for a longer total time than the ST-HFD group, which may contribute to the differences between groups. Our results are consistent with studies showing that obesity duration is associated with diabetes in women (31). Our study is unique, as we assessed the durability of the alterations induced by HFD exposure and show that prolonged recovery did not "normalize" the adipose tissue environment or its lipid storage capacity. Observations of maintained inflammation and insulin resistance are seen in both mice and humans after weight loss (20-21,24-26,32) and is consistent with the genetic evidence that limited peripheral nutrient storage in adipose tissue contributes to diabetes (33).

The limited capacity for eWAT expansion was observed despite a quantitative increase in preadipocytes in formerly obese mice, suggesting that they may have impaired differentiation capacity. This relates to an increase in Col1⁺ preadipocytes, suggesting that they are assuming a myofibroblast phenotype with impaired differentiation (34). In support of this concept, we observed that expression of several critical mature adipocyte-specific genes and proteins were significantly decreased in formerly obese eWAT and remained lower after HFD rechallenge. TNF α neutralization experiments suggested that TNF α may play little, if any, role toward inhibiting adipogenesis in the weight loss context. Other adipogenesis inhibitors exist that have yet to be examined in our system, including, but not limited to, IL-6 (35), Wnt-5a (36), IL-1 β (37,38), macrophage inhibitory factor, and

even fatty acids such as arachidonic acid (39). Future work is needed to clarify if adipose dysfunction in weight loss is due to factors inhibiting adipogenesis versus permanent defects in adipocyte maturation after obesity.

Relative to the ST-HFD group, RC-HFD mice had elevated total and CD11c⁺ ATMs as well as an increase in CD8⁺ adipose tissue T cells. These features resembled the leukocyte increases seen in mice after weight loss and are further evidence of persistence of adipose tissue inflammatory leukocytes once they are established with chronic HFD exposure. This observation is consistent with recent single-cell RNA sequencing studies that have shown that caloric restriction with an HFD sustains a phagocytic ATM population and that gene expression pathways related to inflammation largely resemble obese as opposed to lean mice (40). We have previously shown that macrophage proliferation is a component of this mechanism of this retention; however, new macrophage recruitment or turnover cannot be ruled out (23).

The livers from RC-HFD mice revealed disproportionately increased liver mass with substantially increased steatosis and total triglyceride content compared with the ST-HFD group. The association between adipocyte death and CLS with increased ectopic deposition of lipids into the liver is consistent with other observations (41). In RC-HFD mice, nutrient storage into eWAT was impaired and shifted into iWAT depots; however, this was not sufficient to prevent lipid deposition in the liver, suggesting specific roles for eWAT in preventing steatosis in mice. Steatosis was associated with increased serum concentrations of AST and ALT, indicating liver damage. The ALT to AST ratio was greater than 2:1 in both RC-HFD and LT-HFD mice compared with 1.3:1 in ST-HFD mice. This ratio matches a classical change observed in patients with early stage nonalcoholic fatty liver disease and is associated with obesity and increased risk for type 2 diabetes (42). ST-HFD and RC-HFD mice had similar glucose tolerance with substantially increased liver steatosis. However, fasting insulin levels were almost twofold higher in RC-HFD and LT-HFD mice, indicating increased insulin resistance in the RC-HFD mice, consistent with previous findings showing accrued liver steatosis and impaired liver insulin signaling in weight-cycling models (18,43).

Overall, we were able to identify unique physiological differences associated with weight regain in formerly obese mice. These findings indicate that obesity may result in long-term impairments in adipose tissue function. Future work is needed to investigate the physiological consequences of obesity that remain despite weight loss as well as the mechanisms that limit long-term adipocyte function hypertrophy and hyperplasia. **O**

Acknowledgments

We would like to thank Drs. Cheong-Hee Chang, Philip King, John Osterholzer, Darleen Sandoval (University of Michigan), and Alan Saltiel (University of California San Diego) for critical evaluation of data. This work utilized Core Services from the University of Michigan's Flow Cytometry Core, University of Michigan Animal Phenotyping Core, and University of Michigan's Comprehensive Cancer Center Histology Core.

Funding agencies: This work was carried out with support from the NIH/NIDDK (R01 DK090262 CNL) and the American Diabetes Association (07-12-CD-08). Trainees were supported by NIH NIAID Experimental Training in Immunology T32 AI007413-19 (BFZ and CEP), NIDDK F31 DK103524 and an American Heart Association Predoctoral Fellowship (BFZ), NIH Minority Training Supplement (DK090262-S1

GM-S), and NIDDK T32 DK101357 and F32 DK105676 (LAM). KS is supported by an NIDDK/NIH K08 (K08DK101755).

Disclosure: The authors declared no conflict of interest.

Author contributions: BFZ researched data and wrote manuscript. DL, HRL, CEP, GM-S, KWC, and TAM researched data. KS, JLD, LMG, LAM, and CNL contributed discussion and reviewed/edited manuscript.

Supporting information: Additional Supporting Information may be found in the on-line version of this article.

References

- Clement K, Viguier N, Poitou C, et al. Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. *FASEB J* 2004;18:1657-1669.
- Steckhan N, Hohmann CD, Kessler C, Dobos G, Michalsen A, Cramer H. Effects of different dietary approaches on inflammatory markers in patients with metabolic syndrome: a systematic review and meta-analysis. *Nutrition* 2016;32:338-348.
- Franz MJ, Boucher JL, Rutten-Ramos S, VanWormer JJ. Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. *J Acad Nutr Diet* 2015;115:1447-1463.
- Soleymani T, Daniel S, Garvey WT. Weight maintenance: challenges, tools and strategies for primary care physicians. *Obes Rev* 2016;17:81-93.
- Puzziferri N, Roshk TB 3rd, Mayo HG, Gallagher R, Belle SH, Livingston EH. Long-term follow-up after bariatric surgery: a systematic review. *JAMA* 2014;312:934-942.
- Karmali S, Brar B, Shi X, Sharma AM, de Gara C, Birch DW. Weight recidivism post-bariatric surgery: a systematic review. *Obes Surg* 2013;23:1922-1933.
- Mackie GM, Samocha-Bonet D, Tam CS. Does weight cycling promote obesity and metabolic risk factors? *Obes Res Clin Pract* 2017;11:131-139.
- Mehta T, Smith DL Jr, Muhammad J, Casazza K. Impact of weight cycling on risk of morbidity and mortality. *Obes Rev* 2014;15:870-881.
- Stevens VL, Jacobs EJ, Sun J, et al. Weight cycling and mortality in a large prospective US study. *Am J Epidemiol* 2012;175:785-792.
- Vergnaud AC, Bertrais S, Oppert JM, et al. Weight fluctuations and risk for metabolic syndrome in an adult cohort. *Int J Obes (Lond)* 2008;32:315-321.
- Zhang H, Tamakoshi K, Yatsuya H, et al. Long-term body weight fluctuation is associated with metabolic syndrome independent of current body mass index among Japanese men. *Circ J* 2005;69:13-18.
- Neamat-Allah J, Barrdahl M, Husing A, et al. Weight cycling and the risk of type 2 diabetes in the EPIC-Germany cohort. *Diabetologia* 2015;58:2718-2725.
- Sea MM, Fong WP, Huang Y, Chen ZY. Weight cycling-induced alteration in fatty acid metabolism. *Am J Physiol Regul Integr Comp Physiol* 2000;279:R1145-R1155.
- Kochan Z, Karbowska J, Swierczynski J. The effects of weight cycling on serum leptin levels and lipogenic enzyme activities in adipose tissue. *J Physiol Pharmacol* 2006;57(Suppl 6):115-127.
- Fried SK, Hill JO, Nickel M, DiGirolamo M. Prolonged effects of fasting-refeeding on rat adipose tissue lipoprotein lipase activity: influence of caloric restriction during refeeding. *J Nutr* 1983;113:1861-1869.
- Schofield SE, Parkinson JR, Henley AB, Sahuri-Arisoylu M, Sanchez-Canon GJ, Bell JD. Metabolic dysfunction following weight cycling in male mice. *Int J Obes (Lond)* 2017;41:402-411.
- Barbosa-da-Silva S, Fraulob-Aquino JC, Lopes JR, Mandarim-de-Lacerda CA, Aguila MB. Weight cycling enhances adipose tissue inflammatory responses in male mice. *PLoS One* 2012;7:e39837. doi:https://doi.org/10.1371/journal.pone.0039837
- Anderson EK, Gutierrez DA, Kennedy A, Hasty AH. Weight cycling increases T-cell accumulation in adipose tissue and impairs systemic glucose tolerance. *Diabetes* 2013;62:3180-3188.
- Power C, Thomas C. Changes in BMI, duration of overweight and obesity, and glucose metabolism: 45 years of follow-up of a birth cohort. *Diabetes Care* 2011;34:1986-1991.
- Cancello R, Zulian A, Gentilini D, et al. Permanence of molecular features of obesity in subcutaneous adipose tissue of ex-obese subjects. *Int J Obes (Lond)* 2013;37:867-873.
- Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. *Cell Metab* 2016;23:591-601.
- Kratz M, Hagman DK, Kuzma JN, et al. Improvements in glycemic control after gastric bypass occur despite persistent adipose tissue inflammation. *Obesity (Silver Spring)* 2016;24:1438-1445.
- Zamarron BF, Mergian TA, Cho KW, et al. Macrophage proliferation sustains adipose tissue inflammation in formerly obese mice. *Diabetes* 2017;66:392-406.
- Jung DY, Ko HJ, Lichtman EI, et al. Short-term weight loss attenuates local tissue inflammation and improves insulin sensitivity without affecting adipose inflammation in obese mice. *Am J Physiol Endocrinol Metab* 2013;304:E964-E976.
- Schmitz J, Evers N, Awazawa M, et al. Obesogenic memory can confer long-term increases in adipose tissue but not liver inflammation and insulin resistance after weight loss. *Mol Metab* 2016;5:328-339.
- Kalupahana NS, Voy BH, Saxton AM, Moustaid-Moussa N. Energy-restricted high-fat diets only partially improve markers of systemic and adipose tissue inflammation. *Obesity (Silver Spring)* 2011;19:245-254.
- Martinez-Santibanez G, Cho KW, Lumeng CN. Imaging white adipose tissue with confocal microscopy. *Methods Enzymol* 2014;537:17-30.
- Lee YH, Petkova AP, Granneman JG. Identification of an adipogenic niche for adipose tissue remodeling and restoration. *Cell Metab* 2013;18:355-367.
- Lee YH, Petkova AP, Mottillo EP, Granneman JG. In vivo identification of bipotential adipocyte progenitors recruited by β 3-adrenoceptor activation and high-fat feeding. *Cell Metab* 2012;15:480-491.
- Torti FM, Torti SV, Larrick JW, Ringold GM. Modulation of adipocyte differentiation by tumor necrosis factor and transforming growth factor beta. *J Cell Biol* 1989;108:1105-1113.
- Hu Y, Bhupathiraju SN, de Koning L, Hu FB. Duration of obesity and overweight and risk of type 2 diabetes among US women. *Obesity (Silver Spring)* 2014;22:2267-2273.
- Miller RS, Becker KG, Prabhu V, Cooke DW. Adipocyte gene expression is altered in formerly obese mice and as a function of diet composition. *J Nutr* 2008;138:1033-1038.
- Lotta LA, Gulati P, Day FR, et al. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. *Nat Genet* 2017;49:17-26.
- Keophiphath M, Achard V, Henegar C, Rouault C, Clement K, Lacasa D. Macrophage-secreted factors promote a profibrotic phenotype in human preadipocytes. *Mol Endocrinol* 2009;23:11-24.
- Gustafson B, Smith U. Cytokines promote Wnt signaling and inflammation and impair the normal differentiation and lipid accumulation in 3T3-L1 preadipocytes. *J Biol Chem* 2006;281:9507-9516.
- Bilkovski R, Schulte DM, Oberhauser F, et al. Adipose tissue macrophages inhibit adipogenesis of mesenchymal precursor cells via wnt-5a in humans. *Int J Obes (Lond)* 2011;35:1450-1454.
- Bing C. Is interleukin-1 β a culprit in macrophage-adipocyte crosstalk in obesity? *Adipocyte* 2015;4:149-152.
- Gagnon A, Foster C, Landry A, Sorisky A. The role of interleukin 1 β in the anti-adipogenic action of macrophages on human preadipocytes. *J Endocrinol* 2013;217:197-206.
- Petersen RK, Jorgensen C, Rustan AC, et al. Arachidonic acid-dependent inhibition of adipocyte differentiation requires PKA activity and is associated with sustained expression of cyclooxygenases. *J Lipid Res* 2003;44:2320-2330.
- Weinstock A, Brown EJ, Garabedian ML, et al. Single-cell RNA sequencing of visceral adipose tissue leukocytes reveals that caloric restriction following obesity promotes the accumulation of a distinct macrophage population with features of phagocytic cells [published online July 19, 2019]. *Immunometabolism* 2019;1. doi:https://doi.org/10.20900/immunometab20190008
- Strissel KJ, Stancheva Z, Miyoshi H, et al. Adipocyte death, adipose tissue remodeling, and obesity complications. *Diabetes* 2007;56:2910-2918.
- Sattar N, Forrest E, Preiss D. Non-alcoholic fatty liver disease. *BMJ* 2014;349:g4596. doi:https://doi.org/10.1136/bmj.g4596
- Barbosa-da-Silva S, da Silva NC, Aguila MB, Mandarim-de-Lacerda CA. Liver damage is not reversed during the lean period in diet-induced weight cycling in mice. *Hepatology* 2014;44:450-459.